Please login to the form below

Not currently logged in
Email:
Password:

J&J and Hanmi collaborate on diabetes and obesity

Alliance worth up to$915m
J&J

Johnson and Johnson have entered into an alliance with Hanmi Pharmaceuticals to develop new treatments for diabetes and obesity.

The alliance involves the development and commercialisation of oxyntomodulin-based therapies, including Hanmi's HM12525A, a novel biologic GLP-1/Glucagon dual receptor agonist to treat diabetes and obesity, which is expected to enter phase II trials next year.

James List, global therapeutic area head of cardiovascular and metabolism and J&J's Janssen unit, said: “We are very excited about this agreement with Hanmi and the potential of HM1252A to improve therapeutic options for people living with metabolic diseases.

“Our deep scientific expertise and demonstrated clinical development capabilities support our commitment to aggressively develop and launch transformational therapies for patients with cardiovascular and metabolic diseases.

“We look forward to developing this potential best-in-class therapy.”

Under the terms of the agreement J&J will obtain exclusive worldwide rights, except in China and Korea, to develop and commercialise HM12525A.

Hanmi will receive a payment of $105m and is also eligible to receive up to $810m in potential clinical development, regulatory and sales milestones.

Additionally if HM12525A is successfully commercialised, Hanmi would receive double-digit royalty payments. 

Article by
Nikhil Patel

13th November 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

Enabling market access through outcomes-based pricing
Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...

Infographics